Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Josh Schimmer Analyst Performance

Analyst at Evercore

Josh Schimmer is a stock analyst at Evercore in the medical sector, covering 26 publicly traded companies. Over the past year, Josh Schimmer has issued 31 stock ratings, including buy and hold recommendations. While full access to Josh Schimmer's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Josh Schimmer's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
43 Last 8 Years
Buy Recommendations
90.48% 38 Buy Ratings
Companies Covered
26 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy90.5%38 ratings
Hold9.5%4 ratings
Sell0.0%0 ratings

Out of 42 total stock ratings issued by Josh Schimmer at Evercore, the majority (90.5%) have been Buy recommendations, followed by 9.5% Hold.

Best & Worst Calls

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
26 companies

Josh Schimmer, an analyst at Evercore, currently covers 26 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
26 companies		100.0%

Josh Schimmer of Evercore specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
21 companies		80.8%
MED - DRUGS
3 companies		11.5%
MED - GENERIC DRG
1 company		3.8%
MEDICAL SERVICES
1 company		3.8%

Josh Schimmer's Ratings History at Evercore

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
Export
CompanyReport DateActionReport Date Price12-Month
Price Target		Rating12-Month
Price & ROI		Details
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
7/7/2026Downgrade$42.03Hold
Nuvalent, Inc. stock logo
NUVL
Nuvalent
6/9/2026Downgrade$122.89Neutral
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
5/28/2026Boost Price Target$8.50$30.00Overweight
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
5/26/2026Reiterated Rating$7.87Overweight
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
5/11/2026Boost Price Target$11.27$40.00Overweight
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
5/4/2026Reiterated Rating$2.94$30.00Overweight
Septerna, Inc. stock logo
SEPN
Septerna
3/10/2026Reiterated Rating$28.61$60.00Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3/2/2026Reiterated Rating$234.75$324.00Outperform
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
2/27/2026Boost Price Target$5.24$10.00Overweight
Nuvalent, Inc. stock logo
NUVL
Nuvalent
2/27/2026Boost Price Target$103.03$140.00Overweight
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
2/27/2026Lower Price Target$13.51$100.00Overweight
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
12/18/2025Set Price Target$72.12$72.00
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
12/18/2025Downgrade$72.14Hold
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
12/8/2025Reiterated Rating$67.18$130.00Overweight
Janux Therapeutics, Inc. stock logo
JANX
Janux Therapeutics
12/2/2025Lower Price Target$33.99$150.00Overweight
DiaMedica Therapeutics, Inc. stock logo
DMAC
DiaMedica Therapeutics
11/14/2025Initiated Coverage$5.42Overweight
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
11/6/2025Boost Price Target$79.51$200.00Overweight
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
11/5/2025Boost Price Target$72.38$95.00Overweight
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
11/4/2025Reiterated Rating$39.68$55.00Overweight
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
10/31/2025Boost Price Target$2.72$30.00Overweight
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
10/30/2025Boost Price Target$65.44$110.00Overweight
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
10/29/2025Reiterated Rating$47.98Overweight
Nuvalent, Inc. stock logo
NUVL
Nuvalent
10/15/2025Initiated Coverage$84.66$135.00Overweight
Invivyd, Inc. stock logo
IVVD
Invivyd
10/6/2025Initiated Coverage$1.16$10.00Overweight
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
9/22/2025Lower Price Target$42.34$65.00Outperform
CG Oncology, Inc. stock logo
CGON
CG Oncology
9/8/2025Reiterated Rating$32.81$75.00Overweight
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
9/8/2025Reiterated Rating$15.37Overweight
Septerna, Inc. stock logo
SEPN
Septerna
9/5/2025Reiterated Rating$14.44$25.00Overweight
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
9/5/2025Reiterated Rating$1.61$15.00Overweight
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
8/8/2025Lower Price Target$2.90$8.00Overweight
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
7/29/2025Reiterated Rating$46.59$95.00Overweight
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
7/1/2025Initiated Coverage$5.47$25.00Overweight
Compass Pathways PLC Sponsored ADR stock logo
CMPS
Compass Pathways
6/23/2025Reiterated Rating$2.46$6.00In-Line
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
5/16/2025Boost Price Target$6.50$30.00Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
5/2/2025Boost Price Target$177.67$280.00Outperform
CG Oncology, Inc. stock logo
CGON
CG Oncology
4/28/2025Reiterated Rating$30.06$75.00Overweight
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
3/25/2025Lower Price Target$3.92$20.00Overweight
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
3/10/2025Initiated Coverage$10.13$50.00Overweight
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2/21/2025Reiterated Rating$37.07$95.00Overweight
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2/20/2025Reiterated Rating$187.60$215.00Overweight
Sell Tesla, Buy the New King of FSD Cars (Ad)

In 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, that same stock has earned a 'Very Bullish' rating after forming a major partnership with Nvidia to power AI-driven autonomous vehicles. This barely-known company was selected to handle the complex job of getting Nvidia's self-driving AI safely inside vehicles - positioning it at the center of a massive trend most investors are still missing through Tesla.tc pixel

Get the company's name and ticker free before it goes mainstream

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Top Stock Recommendations by Brokerage